Derek Hwang

Derek Hwang

Materials & Mining Analyst

Materials and mining analyst focused on copper, lithium, and specialty chemicals. Former commodities strategist tracking supply curves, cost positions, and project pipelines. Connects macro demand drivers with company-level execution, permitting risk, and return on invested capital.

Articles 806

Dec 29, 2025 Trade Ideas

Alphabet: Gemini Validation Flywheel Is Real - Trade the Adoption Acceleration

Q3 strength, rising R&D and cash flow point to accelerating monetization; trade idea: tactical long with defined risk.

Alphabet's latest quarterly results show revenue and operating income expansion alongside a meaningful step-up in R&D spending and operating cash flow...

Trade Idea Long
Assessing President Trump's Claims on Ending Multiple Conflicts
Dec 29, 2025 News & Politics

Assessing President Trump's Claims on Ending Multiple Conflicts

An analysis reveals ongoing disputes and complexities behind U.S. presidential assertions of peace achievements

President Donald Trump has asserted that he successfully ended eight wars during his administration. However, a detailed examination shows that many o...

Dec 29, 2025 Finance

Newmont Corporation Shares Decline Amid Gold Price Retraction From Recent Highs

Gold's Pullback from Record Peaks Weighs on Precious Metals Stocks Including Newmont

Newmont Corporation's stock experienced a notable decline on Monday afternoon, coinciding with a retreat in gold prices from recently achieved record ...

Dec 29, 2025 Finance

Genmab Refocuses Pipeline Strategy, Prioritizing High-Impact Late-Stage Products

Discontinuation of Acasunlimab Development Aligns with Strategic Emphasis on Leading Assets Epkinly, Petosemtamab, and Rinatabart Sesutecan

Genmab A/S has announced the cessation of clinical development for acasunlimab, redirecting efforts toward its most promising late-stage candidates. T...

Dec 29, 2025 Finance

Genmab Sharpens Focus on Key Late-Stage Drugs, Ends Acasunlimab Development

Strategic realignment aims to concentrate resources on high-potential candidates including Epkinly, petosemtamab, and Rina-S

Genmab A/S has announced it will cease further clinical development of its immuno-oncology candidate acasunlimab. This decision aligns with the compan...

Dec 29, 2025 Finance

Strategy Inc. Adds 1,229 Bitcoins at $88,568 Each Amid Market Skepticism

Peter Schiff Critiques Five-Year Bitcoin Accumulation Strategy as Ineffective Investment

Strategy Inc. recently expanded its Bitcoin holdings by acquiring 1,229 BTC at an average of $88,568 per coin, spending approximately $108.8 million f...

Dec 29, 2025 Finance

AngloGold Ashanti Shares Slide Amid Sharp Precious Metals Price Corrections

Significant pullbacks in silver and gold prices drive notable declines in AngloGold Ashanti’s market value

AngloGold Ashanti (NYSE: AU) experienced a pronounced stock price decline of 6.5% by midday as precious metals markets underwent a sharp reversal. Sil...

Dec 29, 2025 Finance

Silver Price Drops Sharply Amid Mixed Market Movements; Society Pass, Brand Engagement Network Shares Surge

Commodity prices and equity markets show volatility with key pharmaceutical trials disappointing and new corporate agreements underway

U.S. stock indexes declined on Monday, led by losses in major sectors, while precious metals saw significant price fluctuations. Silver experienced a ...

Dec 29, 2025 Finance

Evaluating Three Resilient Dividend Stocks for Future Growth Potential

Microsoft, Johnson & Johnson, and Coca-Cola offer steady dividends but vary in growth prospects through 2031

Investors seeking reliable income during potential economic downturns often turn to companies with strong dividend histories and stable business model...

Dec 29, 2025 Finance

Target's Stock Pauses After Activist Investor Spurs Rally

Shares Settle Following Surge Amid Strategic Uncertainty and Financial Performance Concerns

Target Corporation's stock experienced a notable rally last Friday after news emerged of an activist investor acquiring a large stake in the company. ...